IRIS
TAGLIAFERRI, PIEROSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.634
AS - Asia 5.714
EU - Europa 2.647
SA - Sud America 1.284
Continente sconosciuto - Info sul continente non disponibili 324
AF - Africa 138
OC - Oceania 23
Totale 18.764
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.279
SG - Singapore 2.602
CN - Cina 1.275
IT - Italia 1.229
BR - Brasile 972
IN - India 582
VN - Vietnam 573
GB - Regno Unito 338
SE - Svezia 332
DE - Germania 262
CA - Canada 247
HK - Hong Kong 145
BD - Bangladesh 114
AR - Argentina 109
FI - Finlandia 96
ID - Indonesia 81
NL - Olanda 66
MX - Messico 61
EC - Ecuador 53
IQ - Iraq 49
RU - Federazione Russa 49
UA - Ucraina 43
ZA - Sudafrica 43
CO - Colombia 41
PK - Pakistan 39
FR - Francia 38
ES - Italia 34
JP - Giappone 33
JO - Giordania 32
RO - Romania 31
PY - Paraguay 30
SA - Arabia Saudita 29
TR - Turchia 26
VE - Venezuela 26
CL - Cile 23
PL - Polonia 23
EG - Egitto 22
EU - Europa 22
IR - Iran 19
AU - Australia 17
PE - Perù 16
AT - Austria 15
CZ - Repubblica Ceca 15
KE - Kenya 14
MA - Marocco 14
MY - Malesia 13
AE - Emirati Arabi Uniti 12
IE - Irlanda 11
LT - Lituania 11
NG - Nigeria 10
PT - Portogallo 10
TN - Tunisia 10
UZ - Uzbekistan 10
EE - Estonia 9
UY - Uruguay 9
GT - Guatemala 8
PH - Filippine 8
AZ - Azerbaigian 7
ET - Etiopia 7
IL - Israele 7
KR - Corea 7
LB - Libano 7
BG - Bulgaria 6
HN - Honduras 6
DO - Repubblica Dominicana 5
JM - Giamaica 5
KZ - Kazakistan 5
NP - Nepal 5
TW - Taiwan 5
AL - Albania 4
CH - Svizzera 4
CR - Costa Rica 4
CU - Cuba 4
CY - Cipro 4
HR - Croazia 4
NZ - Nuova Zelanda 4
SC - Seychelles 4
SN - Senegal 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
BO - Bolivia 3
DZ - Algeria 3
GE - Georgia 3
LK - Sri Lanka 3
PA - Panama 3
PR - Porto Rico 3
PS - Palestinian Territory 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BE - Belgio 2
BN - Brunei Darussalam 2
GR - Grecia 2
GY - Guiana 2
HU - Ungheria 2
KG - Kirghizistan 2
KI - Kiribati 2
KW - Kuwait 2
LV - Lettonia 2
MD - Moldavia 2
Totale 18.443
Salva come PNG Salva come JPEG
Città #
San Jose 1.666
Chandler 826
Singapore 806
Ashburn 750
Santa Clara 463
Hefei 399
Bengaluru 396
Dallas 386
Milan 368
Lawrence 351
Princeton 351
Council Bluffs 338
Chicago 247
Ho Chi Minh City 221
London 221
Beijing 209
Munich 198
Wilmington 190
Ottawa 160
Hong Kong 133
Des Moines 118
Catanzaro 110
Hanoi 108
São Paulo 87
Los Angeles 86
New York 75
Turku 66
Boardman 62
Rome 49
Shanghai 48
Naples 39
Pune 35
Rio de Janeiro 35
Norwalk 34
Brooklyn 31
Guangzhou 31
Phoenix 30
San Francisco 30
Haiphong 29
Helsinki 29
Da Nang 28
Montreal 28
Redmond 28
The Dalles 27
Chennai 24
Amman 23
Tokyo 23
Warsaw 23
Redwood City 22
Manchester 21
Atlanta 20
Thái Bình 20
Curitiba 19
Dhaka 19
Mexico City 19
Baghdad 18
Jeddah 18
Orem 18
Parma 18
Columbus 16
San Nicola Manfredi 16
Shenzhen 16
Stockholm 16
Amsterdam 15
Biên Hòa 15
Guayaquil 15
Johannesburg 15
Porto Alegre 15
Toronto 15
Horia 14
Salvador 14
Seattle 14
Belo Horizonte 13
Boston 13
Quito 13
Reggio Calabria 13
Augusta 12
Aversa 12
Buffalo 12
Cape Town 12
Carbonia 12
Cosenza 12
Denver 12
Nairobi 12
Palermo 12
Spezzano della Sila 12
Campinas 11
Charlotte 11
Delhi 11
Frankfurt am Main 11
Hanover 11
Jakarta 11
Madrid 11
Mountain View 11
Olomouc 11
Recife 11
Ankara 10
Brasília 10
Guarulhos 10
Las Vegas 10
Totale 10.745
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 497
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 146
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 119
miR-22 suppresses DNA ligase III addiction in multiple myeloma 108
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 102
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 100
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 98
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 93
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 89
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 89
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 88
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 84
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 83
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 82
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 82
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 79
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 79
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 79
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 78
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 78
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 78
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 77
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 77
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 77
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 76
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 75
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 75
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 75
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 74
Fetal ontogeny and tumor expression of the early thymic antigen UN1 74
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 74
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 74
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 74
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 74
Mir-34: a new weapon against cancer? 72
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 72
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 71
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 71
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 70
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 70
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 69
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 69
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 68
POLYAMINE UPTAKE BY HUMAN COLON-CARCINOMA CELL-LINE CACO-2 68
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 67
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 67
IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells 67
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 66
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 66
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 65
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 65
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 65
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 65
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 65
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 64
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 64
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 63
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 62
miR-221/222 inhibitors for the treatment of multiple myeloma 62
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 62
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 61
Mir-221/222 are promising targets for innovative anticancer therapy 61
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo 61
Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis 60
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 60
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 60
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation 60
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 60
Anti-myeloma activity of miR-125 mimics 60
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 60
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 59
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 59
COOPERATIVE ANTIPROLIFERATIVE EFFECTS OF 8-CHLORO-CYCLIC AMP AND 528 ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY ON HUMAN CANCER-CELLS 59
2 CLASSES OF CAMP ANALOGS SYNERGISTICALLY INHIBIT P21 RAS PROTEIN-SYNTHESIS AND PHENOTYPIC TRANSFORMATION OF NIH/3T3 CELLS TRANSFECTED WITH HA-MUSV DNA 59
CARDIOVASCULAR MONITORING OF DRUG-RESISTANT LYMPHOMA PATIENTS TREATED WITH EPOCH CHEMOTHERAPY PLUS HIGH-DOSE VERAPAMIL IN CONTINUOUS-INFUSION 59
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 59
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 59
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 58
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 58
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 58
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 58
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 58
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 58
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 58
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 57
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 57
Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel plus /- granulocyte-macrophage colony stimulating factor and low dose aldesleukine 57
PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle 57
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 57
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 57
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 57
miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma 57
Proteomic profiling of inherited breast cancer: Identification of molecular targets for early detection, prognosis and treatment, and related bioinformatics tools 57
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 56
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 56
5-AZA-2'-DEOXYCYTIDINE INDUCES GROWTH-INHIBITION AND UP-REGULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR ON HUMAN EPITHELIAL CANCER-CELLS 56
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 56
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study 56
The non-coding RNA landscape of plasma cell dyscrasias 56
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates 56
Totale 7.369
Salva come PNG Salva come JPEG
Categoria #
all - tutte 190.156
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 190.156
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022960 0 6 12 286 57 19 31 202 96 92 146 13
2022/20232.607 722 77 85 210 279 230 13 167 395 162 217 50
2023/20241.366 311 135 116 94 98 321 41 53 15 48 61 73
2024/20254.168 563 250 184 127 234 521 108 155 486 267 423 850
2025/20268.457 412 897 819 1.510 850 326 1.174 486 1.003 566 275 139
2026/2027517 102 415 0 0 0 0 0 0 0 0 0 0
Totale 18.764